Capricor Therapeutics (CAPR) Invested Capital (2016 - 2025)
Historic Invested Capital for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $83.9 million.
- Capricor Therapeutics' Invested Capital rose 2285.55% to $83.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year increase of 2285.55%. This contributed to the annual value of $145.5 million for FY2024, which is 54359.69% up from last year.
- As of Q3 2025, Capricor Therapeutics' Invested Capital stood at $83.9 million, which was up 2285.55% from $105.0 million recorded in Q2 2025.
- Over the past 5 years, Capricor Therapeutics' Invested Capital peaked at $145.5 million during Q4 2024, and registered a low of -$1.8 million during Q3 2023.
- For the 5-year period, Capricor Therapeutics' Invested Capital averaged around $42.1 million, with its median value being $25.2 million (2022).
- Its Invested Capital has fluctuated over the past 5 years, first plummeted by 11152.53% in 2023, then surged by 391868.54% in 2024.
- Over the past 5 years, Capricor Therapeutics' Invested Capital (Quarter) stood at $32.0 million in 2021, then plummeted by 62.85% to $11.9 million in 2022, then surged by 90.32% to $22.6 million in 2023, then skyrocketed by 543.6% to $145.5 million in 2024, then tumbled by 42.34% to $83.9 million in 2025.
- Its Invested Capital stands at $83.9 million for Q3 2025, versus $105.0 million for Q2 2025 and $127.6 million for Q1 2025.